US FDA Closes Warning Letter Against Glenmark Pharmaceuticals’ Goa Facility

The United States Food and Drug Administration (FDA) has closed its warning letter against Glenmark Pharmaceuticals Limited’s manufacturing facility in Colvale, Goa, following an evaluation of the company’s corrective actions. The development marks an important step in the regulatory review of the facility’s compliance with pharmaceutical manufacturing requirements.

The FDA issued the closeout letter on 23 September 2026 after reviewing the measures taken by Glenmark in response to Warning Letter 320-23-04, dated 22 November 2022. In its communication, the agency stated that the company appeared to have addressed the violations identified in the earlier warning letter.

The closeout reflects the regulator’s assessment of the corrective measures submitted by the company. However, it does not exempt the manufacturer from its continuing obligation to comply with applicable pharmaceutical regulations and quality standards.

The FDA has made it clear that future inspections and regulatory activities will examine whether the corrective measures are adequate and sustainable. The company is therefore expected to maintain the improvements introduced at the facility and ensure that the issues identified previously do not recur.

The agency also clarified that closing the warning letter does not prevent it from taking further regulatory action if subsequent inspections or other regulatory assessments reveal fresh violations. Continued oversight remains part of the FDA’s approach to ensuring that pharmaceutical manufacturers consistently meet established requirements.

The development highlights the role of corrective and preventive actions in resolving regulatory deficiencies. While a closeout letter indicates that the agency considers the previously cited violations to have been addressed, maintaining compliance requires ongoing attention to manufacturing procedures, documentation, quality systems and operational controls.

Glenmark’s Goa facility will remain subject to the FDA’s normal regulatory oversight, with future assessments determining whether the corrective measures continue to meet the required standards. The closeout therefore represents progress in resolving the earlier regulatory concerns rather than a permanent exemption from inspection or enforcement.

06-10-2026